Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.58 |
| ▸ | MMP3 | P08254 | 12/20 | 0.58 |
| ▸ | MMP9 | P14780 | 8/20 | 0.58 |
| ▸ | MMP7 | P09237 | 7/20 | 0.58 |
| ▸ | MMP13 | P45452 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 5/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369631 | 0.91 | MMP1 (0.56) | MMP1MMP3MMP9MMP7MMP13 | |
| SCHEMBL27488462 | 0.91 | MMP9 (0.56) | MMP1MMP3MMP9MMP7MMP13 | |
| Hydrochloric Acid SCHEMBL7349934 | 0.85 | MMP1 (0.75) | MMP1MMP3MMP9MMP7MMP13 | |
| SCHEMBL27583610 | 0.82 | MMP1 (0.54) | MMP1MMP3MMP9MMP7MMP13 | |
| SCHEMBL7533195 | 0.81 | ALDH1A1 (0.64) | MMP1MMP3MMP9MMP7MMP13 | |
| SCHEMBL7533200 | 0.81 | ALDH1A1 (0.64) | MMP1MMP3MMP9MMP7MMP13 | |
| SCHEMBL3914496 | 0.80 | MMP1 (0.58) | MMP1MMP3MMP9MMP7MMP13 | |
| SCHEMBL4581963 | 0.80 | MMP13 (0.52) | MMP1MMP3MMP9MMP7MMP13 | |
| SCHEMBL6269395 | 0.79 | MMP1 (0.76) | MMP1MMP3MMP9MMP7MMP13 | |
| SCHEMBL21035359 | 0.79 | MMP1 (0.52) | MMP1MMP3MMP9MMP7MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |